Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Convertible Debt (2018 - 2024)

Karyopharm Therapeutics' Convertible Debt history spans 7 years, with the latest figure at $171.1 million for Q1 2024.

  • For Q1 2024, Convertible Debt changed 0.48% year-over-year to $171.1 million; the TTM value through Mar 2024 reached $171.1 million, changed 0.48%, while the annual FY2023 figure was $170.9 million, 0.48% changed from the prior year.
  • Convertible Debt reached $171.1 million in Q1 2024 per KPTI's latest filing, roughly flat from $170.9 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $171.1 million in Q1 2024 to a low of $111.8 million in Q1 2020.
  • Average Convertible Debt over 5 years is $156.9 million, with a median of $169.5 million recorded in 2022.
  • Peak YoY movement for Convertible Debt: soared 50.94% in 2021, then increased 0.47% in 2022.
  • A 5-year view of Convertible Debt shows it stood at $117.9 million in 2020, then soared by 43.56% to $169.3 million in 2021, then increased by 0.48% to $170.1 million in 2022, then grew by 0.48% to $170.9 million in 2023, then rose by 0.12% to $171.1 million in 2024.
  • Per Business Quant, the three most recent readings for KPTI's Convertible Debt are $171.1 million (Q1 2024), $170.9 million (Q4 2023), and $170.7 million (Q3 2023).